Table 1 Reference sera used to establish the specificity of COVID-19 IBs
Source | Characteristic | Number of sera |
|---|---|---|
IGeneX (human sera) | Leftover, decoded, pre-pandemic sera received for tick-borne diseases testing | 152 |
CAP and NYSHD Autoimmunity and Allergy (human sera) | Anti-nuclear antibody positive | 5 |
Anti-dsDNA antibody positive | 2 | |
Rheumatoid factor positive | 12 | |
Rheumatoid factor negative | 7 | |
Elevated IgG | 13 | |
Elevated IgE | 4 | |
Normal IgE | 2 | |
NYB Viral Infections (human sera) | Epstein-Barr virus infection | 7 |
Herpes simplex virus infection | 4 | |
Cytomegalovirus infection | 4 | |
Hepatitis C infection | 5 | |
HIV infection | 7 | |
NIH AIDS Reagent Program (human sera) | HIV infection | 3 |
BEI Resources (human sera) | Respiratory syncytial virus infection | 4 |
BEI Resources (goat antisera) | Goat antisera to human influenza A virus proteins | 27 |
Goat antisera to human influenza B virus proteins | 5 |